Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19090289 | 0.85 | OPRM1 (0.42) | OPRM1OPRL1OPRK1OPRD1L3MBTL1 | |
| SCHEMBL13876257 | 0.84 | OPRM1 (0.59) | OPRM1OPRL1OPRK1OPRD1ALOX5 | |
| SCHEMBL9035464 | 0.83 | DRD2 (0.38) | OPRM1OPRL1OPRK1OPRD1L3MBTL1 | |
| SCHEMBL13444795 | 0.79 | ALOX5 (0.54) | OPRM1OPRL1OPRK1OPRD1ALOX5 | |
| SCHEMBL3413530 | 0.78 | ALDH1A1 (0.42) | OPRM1OPRL1OPRK1OPRD1L3MBTL1 | |
| SCHEMBL17318327 | 0.78 | L3MBTL1 (0.36) | OPRM1OPRL1OPRK1OPRD1L3MBTL1 | |
| SCHEMBL10821867 | 0.77 | OPRM1 (0.56) | OPRM1OPRL1OPRK1OPRD1ALOX5 | |
| SCHEMBL14899046 | 0.77 | OPRM1 (0.56) | OPRM1OPRL1OPRK1OPRD1ALOX5 | |
| SCHEMBL15291844 | 0.76 | HRH3 (0.36) | OPRM1OPRK1OPRD1L3MBTL1GAA | |
| SCHEMBL18778704 | 0.76 | POLB (0.41) | OPRM1OPRL1OPRK1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017116213-A1 | LIQUID CRYSTAL COMPOUND AND LIQUID CRYSTAL COMPOSITION CONTAINING SAME | 주식회사 동진쎄미켐 | 2017-07-06 | — | — | WO | disclosed |
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | OPRM1 4527/4885OPRL1 4441/4885OPRK1 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.